Gene · 7913
Papers1,526
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 1,526
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. | Mol Cytogenet | 2022 | 35799207 | PubTator, text mining | PubMed |
| Editor's Note: The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by Both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. | Clin Cancer Res | 2022 | 35775195 | PubTator, text mining | PubMed |
| First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report. | J Thorac Oncol | 2022 | 35773081 | PubTator, text mining | PubMed |
| Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells. | Dis Markers | 2022 | 35769815 | PubTator, text mining | PubMed |
| Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway. | Biomed Res Int | 2022 | 35757470 | PubTator, text mining | PubMed |
| Murine Models of Acute Myeloid Leukemia. | Front Oncol | 2022 | 35756660 | PubTator, text mining | PubMed |
| Potential of DEK proto-oncogene as a prognostic biomarker for colorectal cancer: An evidence-based review. | Mol Clin Oncol | 2022 | 35747597 | PubTator, text mining | PubMed |
| The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis. | Int J Mol Sci | 2022 | 35742899 | PubTator, text mining | PubMed |
| High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. | Biomedicines | 2022 | 35740427 | PubTator, text mining | PubMed |
| Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias. | Front Pharmacol | 2022 | 35734412 | PubTator, text mining | PubMed |
| Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implication of Post-Translational Modifications. | Front Immunol | 2022 | 35720384 | PubTator, text mining | PubMed |
| Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract. | Mod Pathol | 2022 | 35701667 | PubTator, text mining | PubMed |
| Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma. | Chin Med | 2022 | 35698073 | PubTator, text mining | PubMed |
| Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. | Toxicol Appl Pharmacol | 2022 | 35688186 | PubTator, text mining | PubMed |
| From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer. | Int J Mol Sci | 2022 | 35682963 | PubTator, text mining | PubMed |
| Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors. | Int J Mol Sci | 2022 | 35682627 | PubTator, text mining | PubMed |
| New Therapeutic Strategies for Adult Acute Myeloid Leukemia. | Cancers (Basel) | 2022 | 35681786 | PubTator, text mining | PubMed |
| Retraction: The lnc-SNHG1 Gene Is Overexpressed and Correlates with Increased White Blood Cell Count, Poor Induction Treatment Response, and Poor Survival Profile in Adult Acute Myeloid Leukemia | Turk J Haematol | 2022 | 35657175 | PubTator, text mining | PubMed |
| The evolving landscape of prostate cancer somatic mutations. | Prostate | 2022 | 35657155 | PubTator, text mining | PubMed |
| Overlapping group screening for detection of gene-environment interactions with application to TCGA high-dimensional survival genomic data. | BMC Bioinformatics | 2022 | 35637439 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7913/papers?page=15